COVID-19 Guidance on Evaluation of Diagnostic Testing & Methods

The COVID-19 pandemic has created an urgent need for diagnostic testing of patients and populations. In response, a multitude of COVID-19 tests are available to use from many different manufacturers and organisations. FIP has created a counselling information guide to assist practising pharmacists around the world in talking to patients who have questions concerning COVID-19 tests. This joint FIP-ASHP online event will present the newly developed guidance on Evaluation of Diagnostic Testing & Methods, as well as tools for pharmacists developed by the American Society of Health-System Pharmacists (ASHP). Panellists will discuss issues about care and how to manage the risks with evidence is the focus.

Moderator:
Zuzana Kusynova, Lead for Policy, Practice and Compliance, FIP, Netherlands

Panellist:
Mary Ann Kliethermes, Director, Medication Safety and Quality, American Society of Health-System Pharmacists (ASHP), USA

Catherine Duggan, CEO, FIP, Netherlands

Julien Fonsart, Senior specialist in laboratory medicine pharmacist, Hôpital Lariboisière, Université de Paris, France

Ally Dering-Anderson, Clinical Associate Professor in the Department of Pharmacy Practice & Science, University of Nebraska College of Pharmacy, USA

Margaret Underwood, Pharmacy student & FIP Intern, FIP, USA

Jasminka N Sarunac, Lead Pharmacist Investigational drugs/Clinical trial, Pharmacoepidemiologist, John Hunter Hospital, Australia